Rossarin Suwanarusk

List of Publications by Year
in descending order

51 papers	4,188 citations	172457 29 h-index	189892 50 g-index
51 all docs	51 docs citations	51 times ranked	5144 citing authors

#	Article	IF	Citations
1	Improving in vitro continuous cultivation of Plasmodium cynomolgi, a model for P. vivax. Parasitology International, 2022, 89, 102589.	1.3	7
2	Plasmodium vivax binds host CD98hc (SLC3A2) to enter immature red blood cells. Nature Microbiology, 2021, 6, 991-999.	13.3	26
3	Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 46-56.	3.4	4
4	Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stages. Nature Communications, 2019, 10, 3635.	12.8	39
5	In vitro Antimalarial Evaluations and Cytotoxicity Investigations of Carica papaya Leaves and Carpaine. Natural Product Communications, 2019, 14, 1934578X1901400.	0.5	16
6	Quantitative mass spectrometry of human reticulocytes reveal proteomeâ€wide modifications during maturation. British Journal of Haematology, 2018, 180, 118-133.	2.5	40
7	In silico epitope mapping and experimental evaluation of the Merozoite Adhesive Erythrocytic Binding Protein (MAEBL) as a malaria vaccine candidate. Malaria Journal, 2018, 17, 20.	2.3	6
8	Asian G6PD-Mahidol Reticulocytes Sustain Normal Plasmodium Vivax Development. Journal of Infectious Diseases, 2017, 216, 263-266.	4.0	8
9	Strict tropism for CD71+/CD234+ human reticulocytes limits the zoonotic potential of Plasmodium cynomolgi. Blood, 2017, 130, 1357-1363.	1.4	27
10	In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti-P. falciparum and Anti-P. vivax Blood-Stage Antimalarial. Molecules, 2017, 22, 2102.	3.8	12
11	Genomic Analysis Reveals a Common Breakpoint in Amplifications of thePlasmodium vivaxMultidrug Resistance 1 Locus in Thailand. Journal of Infectious Diseases, 2016, 214, 1235-1242.	4.0	29
12	A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609. Journal of Infectious Diseases, 2016, 213, 100-104.	4.0	35
13	Rheopathologic Consequence of Plasmodium vivax Rosette Formation. PLoS Neglected Tropical Diseases, 2016, 10, e0004912.	3.0	20
14	Plasmodium vivax: restricted tropism and rapid remodeling of CD71-positive reticulocytes. Blood, 2015, 125, 1314-1324.	1.4	157
15	Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax. Frontiers in Immunology, 2015, 6, 348.	4.8	44
16	Histone Methyltransferase Inhibitors Are Orally Bioavailable, Fast-Acting Molecules with Activity against Different Species Causing Malaria in Humans. Antimicrobial Agents and Chemotherapy, 2015, 59, 950-959.	3.2	43
17	Methylene blue inhibits the asexual development of vivax malaria parasites from a region of increasing chloroquine resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 124-129.	3.0	23
18	An amidation/cyclization approach to the synthesis of N-hydroxyquinolinones and their biological evaluation as potential anti-plasmodial, anti-bacterial, and iron(II)-chelating agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 607-610.	2.2	10

#	Article	IF	Citations
19	KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission. Antimicrobial Agents and Chemotherapy, 2014, 58, 5060-5067.	3.2	122
20	Glycophorin C (CD236R) mediates vivax malaria parasite rosetting to normocytes. Blood, 2014, 123, e100-e109.	1.4	44
21	Characterization of the Commercially-Available Fluorescent Chloroquine-BODIPY Conjugate, LynxTag-CQGREEN, as a Marker for Chloroquine Resistance and Uptake in a 96-Well Plate Assay. PLoS ONE, 2014, 9, e110800.	2.5	5
22	Targeting Plasmodium PI(4)K to eliminate malaria. Nature, 2013, 504, 248-253.	27.8	377
23	Field-Based Flow Cytometry for Ex Vivo Characterization of Plasmodium vivax and P. falciparum Antimalarial Sensitivity. Antimicrobial Agents and Chemotherapy, 2013, 57, 5170-5174.	3.2	18
24	A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus. Molecular Therapy - Nucleic Acids, 2013, 2, e114.	5.1	79
25	Giemsa-Stained Wet Mount Based Method for Reticulocyte Quantification: A Viable Alternative in Resource Limited or Malaria Endemic Settings. PLoS ONE, 2013, 8, e60303.	2.5	11
26	Significant Biochemical, Biophysical and Metabolic Diversity in Circulating Human Cord Blood Reticulocytes. PLoS ONE, 2013, 8, e76062.	2.5	114
27	Human ex vivo studies on asexual Plasmodium vivax: The best way forward. International Journal for Parasitology, 2012, 42, 1063-1070.	3.1	40
28	Cerebral malaria. Virulence, 2012, 3, 193-201.	4.4	118
29	Cryopreserved Plasmodium vivax and cord blood reticulocytes can be used for invasion and short term culture. International Journal for Parasitology, 2012, 42, 155-160.	3.1	44
30	Genetic Diversity in New Members of the Reticulocyte Binding Protein Family in Thai Plasmodium vivax Isolates. PLoS ONE, 2012, 7, e32105.	2.5	12
31	Plasmodium vivax Adherence to Placental Glycosaminoglycans. PLoS ONE, 2012, 7, e34509.	2.5	70
32	A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite development. Scientific Reports, 2011, 1, 118.	3.3	175
33	A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivax. Blood, 2011, 118, e74-e81.	1.4	120
34	Considerations on the use of nucleic acid-based amplification for malaria parasite detection. Malaria Journal, 2011, 10, 323.	2.3	34
35	Plasmodium vivax lineages: geographical distribution, tandem repeat polymorphism, and phylogenetic relationship. Malaria Journal, 2011, 10, 374.	2.3	26
36	The Presence of Leukocytes in Ex Vivo Assays Significantly Increases the 50-Percent Inhibitory Concentrations of Artesunate and Chloroquine against Plasmodium vivax and Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2011, 55, 1300-1304.	3.2	10

#	Article	IF	Citations
37	Methotrexate Is Highly Potent Against Pyrimethamine-Resistant Plasmodium vivax. Journal of Infectious Diseases, 2011, 203, 207-210.	4.0	14
38	Spiroindolones, a Potent Compound Class for the Treatment of Malaria. Science, 2010, 329, 1175-1180.	12.6	1,031
39	Plasmodium vivax Susceptibility to Ferroquine. Antimicrobial Agents and Chemotherapy, 2010, 54, 2228-2230.	3.2	17
40	On the Cytoadhesion ofPlasmodium vivaxâ€“Infected Erythrocytes. Journal of Infectious Diseases, 2010, 202, 638-647.	4.0	259
41	Effective and cheap removal of leukocytes and platelets from Plasmodium vivax infected blood. Malaria Journal, 2009, 8, 115.	2.3	86
42	Plasmodium vivax trophozoites insensitive to chloroquine. Malaria Journal, 2008, 7, 94.	2.3	55
43	Amplification ofpvmdr1Associated with Multidrugâ€ResistantPlasmodium vivax. Journal of Infectious Diseases, 2008, 198, 1558-1564.	4.0	117
44	Stronger Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against Clinical Isolates of Plasmodium vivax than against Those of P. falciparum. Antimicrobial Agents and Chemotherapy, 2008, 52, 2435-2441.	3.2	34
45	Determinants of In Vitro Drug Susceptibility Testing of Plasmodium vivax. Antimicrobial Agents and Chemotherapy, 2008, 52, 1040-1045.	3.2	119
46	Comparison of three molecular methods for the detection and speciation of Plasmodium vivax and Plasmodium falciparum. Malaria Journal, 2007, 6, 124.	2.3	64
47	Chloroquine Resistant Plasmodium vivax: In Vitro Characterisation and Association with Molecular Polymorphisms. PLoS ONE, 2007, 2, e1089.	2.5	187
48	Plasmodium vivax: Isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates. Experimental Parasitology, 2006, 114, 34-39.	1.2	47
49	Plasmodium vivax genetic diversity: microsatellite length matters. Trends in Parasitology, 2006, 22, 399-401.	3.3	25
50	The Deformability of Red Blood Cells Parasitized byPlasmodium falciparumandP. vivax. Journal of Infectious Diseases, 2004, 189, 190-194.	4.0	162
51	Medicinal Plants and Malaria. , 0, , .		6